Ironwood Pharmaceuticals Reports Q2 2025 Results; LINZESS U.S. Net Sales $248M, GAAP Net Income $23.6M

IRONWOOD PHARMACEUTICALS INC

2025-Q2 EPS reported -$0.09 vs consensus $0.04 ▼ miss (-320.6%)

LINZESS generated $248M in U.S. net sales in Q2 2025, with 10% year-over-year EUTRx demand growth.
GAAP net income was $23.6M in Q2 2025, compared to a net loss of $0.9M in Q2 2024.
Adjusted EBITDA was $50.1M in Q2 2025, up from $36.5M in Q2 2024.
Company plans to align with FDA on confirmatory Phase 3 trial design for apraglutide in Q4 2025.
Ironwood is actively progressing a strategic alternatives review to maximize shareholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.